Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) shares reached a new 52-week low during trading on Monday . The ...

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have been given a consensus recommendation of “Buy” by the ...

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025On track to initiate a proof-of-concept study in ...

Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life extended ...

MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka”) (Nasdaq: ORKA), a biotechnology ...

Dec. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of ...

Oruka Therapeutics (ORKA) announced that it is expected to be added to the Nasdaq Biotechnology Index (NBI). Oruka’s addition will become effective prior to market open on Monday, December 23rd ...

Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life ...

Oruka Therapeutics, Inc. MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to ...

Oruka Therapeutics, Inc. - 8-K, Current Report 14.11. Oruka Therapeutics files to sell 8.72M shares of common stock for holders 14.11. Oruka Therapeutics, Inc. - S-1, General form for registration ...